Cloud DX Inc (OTCMKTS:CDXFF) Stock Pulls Back After The Big Jump
Shares of Cloud DX Inc (OTCMKTS:CDXFF) have pulled back about 10% in the past week. However, the stock is still up 40% in the past month.
Market Stats
On Thursday, CDXFF stock ended flat at $0.2270 with more than 3.5k shares, compared to its average volume of 5.9K shares. The stock has moved within a range of $0.2270 – 0.2270 after opening trading at $0.23.
Cloud DX Gets Partnership Funding to Proceed on Clinical Research of Wearable Vital Sign Monitoring Device – Pulsewave 2.0
Cloud DX Inc (OTCMKTS:CDXFF) has announced about receiving new partner funding from the New Brunswick Health Research Foundation (NBHRF) – it is for supporting ongoing clinical calibration and subsequent validation trials with the Cloud DX Pulsewave 2.0 wrist-worn vital sign monitoring device.
Over the next three years, Cloud DX will match the NBHRF Strategic Initiative Grant two to one, for supporting the ongoing research and development led by Dr. Brunt and Dr. Teskey and their teams at Cardiovascular Research New Brunswick (CVR NB), Dalhousie Medicine New Brunswick (DMNB), University of New Brunswick (UNB) and the IMPART investigator team. The Department of Cardiology at the New Brunswick Heart Center at the Saint John Regional Hospital (SJRH), part of the Horizon Health Network, is all set to assist in the research.
Cloud DX is now actively involved in clinically calibrating the PAD-2A device in preparation for subsequent clinical validation with the ISO 2020_AMD 1 universal protocol. The validation data has to be submitted to Health Canada and the FDA for licensing and clearance, respectively, thus meeting federal regulatory requirements in order to serve tmarket needs in Canada and the United States.
The company will include Pulsewave 2.0 device in its Connected Healthvirtual care and remote patient monitoring solution, once the research team clinically validates it, and the federal regulatory agencies issue the proper clearance.
Key Quote
Dr. Robert Teskey, an Interventional Cardiologist with the Horizon Health Network, New Brunswick Heart Centre added that “Clinically accurate vital sign monitoring at home is essential for our cardiac patients. This funding will support the ongoing clinical calibration and validation of the Cloud DX, Inc. Pulsewave 2.0, the non-invasive vital sign monitoring device.”
